Tumori最新文献

{"title":"The use of PSA testing over more than 20 years: A population-based study in North-Eastern Italy.","authors":"Martina Taborelli,&nbsp;Federica Toffolutti,&nbsp;Ettore Bidoli,&nbsp;Luigino Dal Maso,&nbsp;Stefania Del Zotto,&nbsp;Elena Clagnan,&nbsp;Michele Gobbato,&nbsp;Diego Serraino,&nbsp;Silvia Franceschi","doi":"10.1177/03008916221128343","DOIUrl":"https://doi.org/10.1177/03008916221128343","url":null,"abstract":"<p><strong>Objective: </strong>To describe the practice of prostate-specific antigen (PSA) testing over more than 20 years in Friuli Venezia Giulia (FVG), North-Eastern Italy.</p><p><strong>Methods: </strong>A population-based, ecological study was conducted using information derived from regional administrative health-related databases. Data on PSA and prostate biopsies performed on resident men aged ⩾45 years from 1998 to 2019 were retrieved. PSA and biopsy rates were calculated as the number of men who had at least one such procedure in each calendar year over the mean resident male population of the same year. Temporal trends were analyzed using joinpoint regression (annual percentage change -APC).</p><p><strong>Results: </strong>A total of 2,502,670 PSA were made between 1998 to 2019 in men aged ⩾45 years. The number of PSA steadily increased from 51,055 in 1998-1999 to 134,504 in 2010-2011, then dropped to 122,080 in 2018-2019. Significant changes in the slopes of PSA rates emerged in 2002 and 2009: the largest increase occurred during 1998-2002 (APC 18.4), followed by a smaller increase in 2002-2009 (APC 3.4) and a subsequent reduction (APC -2.5). Similar patterns emerged for all ages, but the decrease since 2009 was smaller for men aged ⩾65 years. An upward trend emerged in biopsy rate from 1998 to 2001 (APC 13.0), followed by a smaller increase until 2007 (APC 5.7) and a subsequent decrease. Biopsies as percentage of PSA decreased from 3.2% to 2.2%, particularly in those aged ⩾75 years.</p><p><strong>Conclusions: </strong>Although overall declining PSA rates have been observed in FVG since 2009, rates remained higher in the ⩾65-year-old group than in the 45-64-year-old group.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"406-412"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/89/10.1177_03008916221128343.PMC10363938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration of androgen deprivation with radiotherapy for high-risk or locally advanced prostate cancer: A network meta-analysis.","authors":"Fausto Petrelli,&nbsp;Agostina De Stefani,&nbsp;Ivano Vavassori,&nbsp;Federica Motta,&nbsp;Andrea Luciani,&nbsp;Francesca Trevisan","doi":"10.1177/03008916231153439","DOIUrl":"https://doi.org/10.1177/03008916231153439","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate various outcomes of different lengths of androgen deprivation therapy in high- and very-high-risk prostate cancer, we conducted a network meta-analysis of randomized trials. The treatment of high-risk PC comprises the use of radical radiotherapy associated with various durations of androgen deprivation therapy, with luteinizing hormone releasing hormone analogues initiated during or immediately before the beginning of radiation.</p><p><strong>Methods and materials: </strong>This study followed the PRISMA extension statement to report network meta-analyses. We systematically searched online databases, including MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, for all randomized trials published up to April 2022. The primary outcomes were overall survival, prostate cancer-specific mortality, and metastasis-free survival. Network meta-analyses were performed under a Bayesian framework using the \"gemtc\" package (https://gemtc.drugis.org).</p><p><strong>Results: </strong>The network meta-analysis included 12 studies (10 treatments) on overall survival outcomes. None of the arms showed superiority to radiotherapy alone with respect to overall deaths. Nine studies and 10 treatment arms had prostate cancer-specific mortality data. Overall, 36 months of adjuvant androgen deprivation therapy resulted in a better outcome than radiotherapy alone, three months of neoadjuvant androgen deprivation therapy, or 12 or 24 months of adjuvant androgen reprivation therapy, and it was the better treatment (73%) in terms of cancer mortality. Treatment involving luteinizing hormone releasing hormone analogues for 6 months before and during radiotherapy ranked the highest in reducing distant metastases (42%).</p><p><strong>Conclusions: </strong>We found that 36 months of adjuvant androgen deprivation therapy after radiotherapy was the optimal duration of endocrine treatment with regard to cancer mortality for high-risk and locally advanced prostate cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"424-429"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The distinct experience of supportive care needs among cervical cancer patients: A qualitative study.","authors":"Kamala Dhakal,&nbsp;Panpan Wang,&nbsp;Joanes Faustine Mboineki,&nbsp;Mikiyas Amare Getu,&nbsp;Changying Chen,&nbsp;Daya Laxmi Shrestha","doi":"10.1177/03008916221128064","DOIUrl":"https://doi.org/10.1177/03008916221128064","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with cervical cancer report experiencing physical, psychological, economic, and social problems daily. An exploration of supportive care needs is important for patients and their families to cope with diagnosis, treatment, recovery or even death.</p><p><strong>Objective: </strong>This study explores the perceived supportive care needs of Nepali patients with cervical cancer who are undergoing cancer treatment.</p><p><strong>Methods: </strong>A descriptive qualitative research design was utilized with semi-structured interviews to probe patients with cervical cancer's supportive care needs. The study was conducted at a cancer-specific hospital in Nepal. Purposive sampling was used to recruit 30 patients with cervical cancer. Qualitative thematic analysis techniques were employed to identify the supportive care needs of Nepalese patients with cervical cancer.</p><p><strong>Results: </strong>Supportive care needs were identified with five main themes and sixteen sub-themes: 1) psychological trauma (regret on delaying medical consultation, fear of disease, death and dying, ambivalence about the future and treatment, feeling of loss, caring/rearing of children, feeling and burden to partner/family); 2) financial distress (loss of income and challenges with treatment costs); 3) sexual disharmony; 4) physical dependency on others for day-to-day care and; 5) hunger for information (cause of disease, prognosis of disease, dietary counseling, and information on sexuality).</p><p><strong>Conclusion: </strong>Recognizing the supportive care needs of patients with cervical cancer during treatment by health care professional and family members is vital to facilitate optimal care at the hospital and home for overall improvement in the patient's quality of life. Acknowledgment that the expensive treatment regime creates an economic and psychological burden for the patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"394-405"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demystifying neuroblastoma malignancy through fractal dimension, entropy, and lacunarity.","authors":"Irene Donato,&nbsp;Kiran K Velpula,&nbsp;Andrew J Tsung,&nbsp;Jack A Tuszynski,&nbsp;Consolato M Sergi","doi":"10.1177/03008916221146208","DOIUrl":"https://doi.org/10.1177/03008916221146208","url":null,"abstract":"<p><strong>Purpose: </strong>Neuroblastoma is a pediatric solid tumor with a prognosis associated with histology and age of the patient, which are the parameters of the well-established current classification (Shimada classification). Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor. Therefore, there is a continuous need to stratify the children suffering from this tumor. A mathematical and computational approach is proposed to enable automatic and precise cancer diagnosis on the histological slide.</p><p><strong>Methods: </strong>We targeted the complexity of neuroblastoma by calculating its image entropy (<i>S</i>), fractal dimension (FD), and lacunarity (λ) in a combined mathematical code. First, we tested the proposed method for patient-derived glioma images. It allowed distinguishing between normal brain tissue, grade II, and grade III glioma, which harbor different outcomes.</p><p><strong>Results: </strong>In neuroblastoma, our analysis of image's FD, <i>S</i>, and λ combined with a machine learning algorithm automatically predicted tumor malignancy with a receiver operating characteristic curve of 0.82. FD, <i>S</i>, and λ distinguish between neuroblastoma and ganglioneuroma, but they only partially differentiate between the normal samples and the other classes. Ganglioneuroma, the most differentiated form, and poorly-differentiated neuroblastoma display different values of FD, <i>S</i>, and λ.</p><p><strong>Conclusions: </strong>FD, <i>S</i>, and λ of imaging recognize groups in neuroblastic tumors. We suggest that future studies including these features may challenge the current Shimada classification of neuroblastoma with categories of favorable and unfavorable histology. It is expected that this methodology could trigger multicenter studies and potentially find practical use in the clinical setting of children's hospitals worldwide.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"370-378"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New perspectives: Glioma in adult patients.","authors":"Antonio Silvani","doi":"10.1177/03008916231159716","DOIUrl":"https://doi.org/10.1177/03008916231159716","url":null,"abstract":"<p><p>The purpose of this editorial is to consider some of the aspects of the diagnosis and treatment of adult gliomas. These are rare diseases with all their limitations. Innovations in diagnosis and therapy and their constraints are analyzed and compared with the current treatment reality. Aspects affecting these patients' quality of life are highlighted.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"350-355"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review.","authors":"Xing Yan,&nbsp;Changhong Liu","doi":"10.1177/03008916221101927","DOIUrl":"https://doi.org/10.1177/03008916221101927","url":null,"abstract":"<p><p>Lung cancer is one of the most malignant cancers in China with a rising incidence rate. Despite the fact that surgical treatment is the only possible cure for lung cancer, its long-term efficacy is compromised by the high level of postoperative local recurrence rate. Minimal residual disease is the leading cause of tumor recurrence, yet the suggested combination of clinical, radiological and serological (carcinoembryonic antigen) tests fails to reveal the underlying residual tissue in all stage I-III lung cancer cases, which makes tumor recurrence surveillance timely. Through monitoring circulating tumor DNA, the minimal residual disease level can be accessed and provide guidance for more precise postoperative personalized treatment, and its scientific feasibility can revolutionize lung cancer therapy. In the present review we summarized the progress of circulating tumor DNA in lung cancer minimal residual disease detection and discussed its application value in guiding precise treatment of lung cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"356-362"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9842492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central venous catheters-related-thrombosis and risk factors in oncological patients: A retrospective evaluation of recent risk scores.","authors":"Ida Taglialatela,&nbsp;Luigi Mariani,&nbsp;Katia Fiorella Dotti,&nbsp;Laura Di Vico,&nbsp;Maria Neve Pisanu,&nbsp;Claudia Facchinetti,&nbsp;Filippo De Braud,&nbsp;Laura Anna Maria Ferrari","doi":"10.1177/03008916221111419","DOIUrl":"https://doi.org/10.1177/03008916221111419","url":null,"abstract":"<p><strong>Background: </strong>Insertions of central venous catheters (CVC) has become a common practice in Onco-Hematologic Units to administer systemic treatments. Unfortunately they can cause complications influencing patient's care-pathway significantly. Oncological patients have a higher thrombotic risk than the general population, therefore specific recent risk scores are spreading through the clinical practice, such as Khorana, Protecht, COMPASS-CAT, and Michigan scores.</p><p><strong>Methods: </strong>A retrospective cohort of 177 out of a total of 3046 outpatients accessing the Medical Day Hospital of Istituto Nazionale Tumori di Milano from March 2019 to February 2021 aged ⩾ 18 years who developed CVC complications was analyzed extracting clinical data from their medical records. Focusing on the risk factors, especially through recent risk scores to estimate the thrombotic risk we used Wilcoxon-test for continuous variables and the Pearson-Chi-Square test for categorical variables.</p><p><strong>Results: </strong>Anticoagulants resulted a protective factor mostly for partial CVC occlusion (p = 0.0001), preventing CVC occlusions. CVC occlusions were significantly associated with epitelial tumor histotype, (p = 0.0061). Complete CVC occlusions were significantly associated with peripherical inserted central venous catheters (PICC) (p < 0.0001). Catheter-related-thrombosis (CRT) was significantly associated with peripherical-inserted-central-venous-catheter, both when it was diagnosed clinically (p = 0.0121) and radiographically (p = 0.0168).There was a strong association between CRT and a high grade of Khorana Score (p = 0.0195), Protecht Score (p = 0.0412), COMPASS-CAT Score (p = 0.0027). A positive statistical trend was observed between the Michigan Score and CRT in patients carrying PICC (p = 0.053).</p><p><strong>Conclusions: </strong>There are many different and various factors associated with higher or lower risk of CVC thrombotic complications, so it could be useful to test the recent risk scores to estimate thrombotic risk in oncological patients in clinical practice.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"363-369"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/d2/10.1177_03008916221111419.PMC10363937.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9867220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.","authors":"Nicola Nicolai,&nbsp;Sebastiano Nazzani,&nbsp;Antonio Tesone,&nbsp;Alberto Macchi,&nbsp;Luigi Piva,&nbsp;Roberto Salvioni,&nbsp;Silvia Stagni,&nbsp;Tullio Torelli,&nbsp;Edoardo Agostini,&nbsp;Francesco Celso,&nbsp;Patrizia Giannatempo,&nbsp;Giuseppe Procopio,&nbsp;Barbara Avuzzi,&nbsp;Rodolfo Lanocita,&nbsp;Laura Cattaneo,&nbsp;Mario Catanzaro,&nbsp;Davide Biasoni","doi":"10.1177/03008916221112697","DOIUrl":"https://doi.org/10.1177/03008916221112697","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with stage II germ-cell tumours (GCT) usually undergo radiotherapy (seminoma only) or chemotherapy. Both strategies display a recognised risk of long-term side effects. We evaluated retroperitoneal lymph node dissection (RPLND) as exclusive treatment in stage II GCT.</p><p><strong>Methods: </strong>Between 2008 and 2019 included, 66 selected stage II GCT patients underwent primary open (O-) or laparoscopic (L-)RPLND. Type of procedure and extent of dissection, operative time, node rescue, hospital stay, complications (according to Clavien-Dindo), administration of chemotherapy, relapse and site of relapse were evaluated.</p><p><strong>Results: </strong>Five patients had pure testicular seminoma. Nineteen (28.8%) had raised markers prior to RPLND; 48 (72.7%), 16 (24.2%) and two (3.0%) were stage IIA, IIB and IIC, respectively. O-RPLND and unilateral L-RPLND were 36 and 30 respectively. Six stage II A patients (12.5%) had negative nodes. Four patients underwent immediate adjuvant chemotherapy. One patient was lost at follow-up. After a median follow-up of 29 months, 48 (77.4%) of the 62 patients undergoing RPLND alone remained recurrence-free; one patient had an in-field recurrence following a bilateral dissection. According to procedure, number of rescued nodes (O-RPLND: 25. IQR 21-31; L-RPLND: 20, IQR 15-26; p: 0.001), hospital stay (L-RPLND: 3 days, IQR 3-4; O-RPLND: 6 days, IQR 5-8; p: .001) and grade ≥2 complications (L-RPLND 7%, O-RPLND 22%; p: 0.1) were the only significant differences.</p><p><strong>Conclusion: </strong>Primary RPLND is safe in stage II GCT, including seminoma, and may warrant a cure rate greater than 70%. When feasible, L-RPLND may be as effective as O-RPLND with better tolerability.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"379-386"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/42/10.1177_03008916221112697.PMC10363949.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcome measurements in post-mastectomy implant-based breast reconstruction and radiotherapy: Analysis of BREAST-Q data.","authors":"Laura Sala,&nbsp;Stefano Bonomi,&nbsp;Chiara Maura Ciniselli,&nbsp;Paolo Verderio,&nbsp;Marta Pastori,&nbsp;Andrea Maurichi,&nbsp;Umberto Cortinovis","doi":"10.1177/03008916221107715","DOIUrl":"https://doi.org/10.1177/03008916221107715","url":null,"abstract":"<p><strong>Background: </strong>Breast reconstruction has become a standard of care in patients undergoing mastectomy, greatly improving their quality of life. An increasing number of patients-reported outcome measurements (PROMs) have been developed over the years to better analyze patients' subjective overall experience. BREAST-Q is the PROMs for breast surgery introduced in our practice to assess patients' experiences when undergoing implant-based breast reconstruction and radiotherapy along with the use of Peak Plasma Blade and acellular dermal matrix.</p><p><strong>Methods: </strong>The pre-operative version of the Reconstruction BREAST-Q was administered to all 88 patients enrolled between December 2017 and December 2018 in the Plastic Reconstructive Surgery Unit at Fondazione IRCCS Istituto Nazionale Tumori Milano through person-to-person interviews, while the post-operative version was administered to the 75 patients who completed a 12-month follow-up (four patients died during one-year follow-up and nine patients had major complications). The survey areas highlighted were: satisfaction with breast, psychosocial well-being, physical well-being and sexual well-being.</p><p><strong>Results: </strong>From BREAST-Q questions regarding Satisfaction With The Appearance Of The Breast and Psychosocial Well-Being outcomes showed significant improvement from pre-operative data, as well as with Satisfaction With Overall Care, with the exception of Physical Well-Being Chest.</p><p><strong>Conclusions: </strong>BREAST-Q allows the assessment of patients' perception, not only for surgical results, but also for the overall experience with surgeons and medical staff.The women enrolled in our study reported an overall good patient satisfaction in most of the analyzed fields.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 3","pages":"295-300"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/02/10.1177_03008916221107715.PMC10248303.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9951940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blooming in the rain.","authors":"Matteo Silva,&nbsp;Massimo Guglielmi,&nbsp;Carlo Alfredo Clerici,&nbsp;Maura Massimino,&nbsp;Andrea Ferrari","doi":"10.1177/03008916231163933","DOIUrl":"https://doi.org/10.1177/03008916231163933","url":null,"abstract":"","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 3","pages":"342-343"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9666680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}